Alpha IVF Group’s 9M25 PATMI rises 6.3% to RM41.4 million
• Driven by continued influx of foreign patients from Indonesia and China
KUALA LUMPUR, Malaysia, 22 April 2025 – Leading fertility care specialist, Alpha IVF Group Berhad (“Alpha IVF Group”, “the Group”, “阿儿法国际辅助生殖集团”, Bloomberg: ALPHA MK, Bursa Ticker: 0303) reported a 6.3% year-on-year increase in profit after tax and minority interests (PATMI) to RM41.4 million for the nine months ended 28 February 2025 (9M25), compared to RM38.9 million in the previous corresponding period.
The improved performance was primarily driven by continued growth in the Group’s foreign patient segment in its Malaysian operations during the period. The growing foreign patient base reflects Alpha IVF Group’s strong regional positioning and reputation for delivering world-class fertility treatment.
Malaysia’s operations continued to be the main revenue contributor, generating RM110.7 million or 87.3% of the Group’s total revenue in 9M25, with the remainder coming from its Singapore operations. The sustained momentum in Malaysia’s operations also drove a 5.0% increase in the Group’s revenue to RM126.8 million from RM120.8 million previously.
The contribution of foreign patients to Malaysia’s operations saw significant growth in 9M25, rising to RM78.9 million or 71.2% of total revenue, from RM56.7 million or 58.2% in 9M24, mainly due to the higher influx of patients from Indonesia and China. Among the foreign patient base, Indonesian patients were the largest contributor, accounting for RM43.8 million or 39.6% of Malaysia’s operation revenue, followed by Chinese patients, who contributed RM24.2 million or 21.9%.
“As we move forward, our strategy remains consistent – to grow both organically via our existing centres and through regional expansion initiatives. We believe the steps we are taking to expand access to our fertility treatment services in the region will not only strengthen our regional presence but also deliver long-term value for our shareholders.”
Dato’ Dr Colin Lee Soon Soo (拿督 李顺树医生)
Group Managing Director, Alpha IVF
For the third quarter ended 28 February 2025 (3Q25), the Group’s revenue marginally decreased to RM40.6 million from RM40.7 million in the previous year’s same quarter. PATMI declined to RM11.9 million from RM13.6 million, primarily due to lower contributions from Singapore operations and initial costs related to ongoing expansion initiatives.
Since its initial public offering (IPO), the Group has expanded its operational footprint from three to six facilities. This includes the launch of Alhaya, a full-fledged IVF fertility centre, as well as two new sales representative offices in China to better serve the growing international market. In line with the Group’s post-IPO growth strategy, Alpha IVF Group is targeting to operate a total of at least 15 facilities, covering Malaysia, Indonesia, China, the Philippines, and Singapore by the financial year ending 31 May 2027.
